GeneDx Holdings Corp. has announced its preliminary financial results for 2025 and shared its outlook for 2026. For the full year 2025, the company expects revenues of approximately $427 million, representing a 41% increase year-over-year. Exome and genome revenue is projected to grow by 54% for the year, or 58% when excluding a one-time benefit in 2024. Exome and genome volume growth is expected to exceed 30% for 2025, with the fourth quarter accelerating to 34.3%. The adjusted gross margin for both the full year and fourth quarter of 2025 is anticipated to be 71%. Looking ahead to 2026, GeneDx forecasts revenues between $540 million and $555 million, with exome and genome revenue and volume expected to grow by 33% to 35%. The company also expects an adjusted gross margin of at least 70% and positive adjusted net income for the year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Genedx Holdings Corp. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260112893074) on January 12, 2026, and is solely responsible for the information contained therein.